Michael Wyatt to Biosimilar Pharmaceuticals
This is a "connection" page, showing publications Michael Wyatt has written about Biosimilar Pharmaceuticals.
Connection Strength
0.299
-
Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions. Lancet Oncol. 2020 12; 21(12):e575-e588.
Score: 0.180
-
Regulatory and clinical considerations for biosimilar oncology drugs. Lancet Oncol. 2014 Dec; 15(13):e594-e605.
Score: 0.119